Boston Scientific Corporation filings document the regulatory record of a global medical technology company with device and therapy portfolios for cardiovascular, respiratory, digestive, oncological, neurological and urological conditions. Recent 8-K reports furnish operating results, clinical-trial announcements and other material events tied to products such as WATCHMAN and EKOS.
Proxy and governance filings cover director elections, executive compensation, stockholder votes, board committee matters and amendments to the company’s certificate of incorporation. Additional disclosures address capital resources and financing arrangements, including revolving credit terms, along with common-stock reporting, senior debt references, risk-related governance and formal exhibits filed under the Exchange Act.
Boston Scientific executive Arthur C. Butcher reported a discretionary rebalancing transaction in the company’s 401(k) plan involving 6,851 shares of common stock at $75.76 per share. This was an indirect transaction under the company’s 401(k) Retirement Savings Plan, treated as a discretionary transaction under Rule 16b-3(f).
Following this plan-related activity, his indirect 401(k) holdings were 20,205 shares of Boston Scientific common stock, and his directly held position was 55,792 shares. The filing reflects a retirement-plan allocation decision rather than a traditional open-market purchase or sale.
Boston Scientific (BSX) agreed to acquire Penumbra in a cash-and-stock merger under an Agreement and Plan of Merger dated January 14, 2026. At the Effective Time, each issued Penumbra share (other than excluded shares) will convert into the right to receive either $374.00 in cash or 3.8721 Boston Scientific shares, subject to the proration provisions of the Merger Agreement.
The Merger Agreement fixes the aggregate allocation at 73.26% of Penumbra shares to receive cash and 26.74% to receive stock (rounded to whole shares). Penumbra stockholders may elect cash, stock or a mix; elections are subject to proration and no fractional Boston Scientific shares will be issued. The Merger requires Penumbra stockholder approval at a special meeting and customary regulatory clearances.
Boston Scientific arranged new bank financing to support its planned acquisition of Penumbra and refresh its liquidity facilities. The company entered into a $3.0 billion multi-year revolving credit agreement maturing on February 26, 2031, with interest tied to its credit rating and a required maximum leverage ratio.
It also put in place a $2.0 billion 364-day revolving credit facility and a $6.0 billion delayed draw term loan agreement, split into two 364-day tranches that can be drawn at the Penumbra acquisition closing. Tranche B borrowings must later be repaid or refinanced with proceeds from future equity or debt offerings, and both the revolvers and term loans carry ticking fees on undrawn commitments.
Following these new agreements, Boston Scientific terminated its prior revolving credit facility originally dated May 10, 2021, consolidating its bank financing under the new 2026 credit agreements.
Boston Scientific Corp director Christophe Pierre Weber filed an initial statement of beneficial ownership on Form 3. The filing lists him as a director of the company and does not report any purchase, sale, acquisition, or disposition transactions in the company’s securities.
Boston Scientific Corporation director Cathy R. Smith filed an initial ownership report on Form 3. The filing shows indirect ownership of 141 shares of common stock as of February 18, 2026, held "By Trust." This is a disclosure of existing holdings, not a reported trade.
Boston Scientific Corporation expanded its Board of Directors and significantly increased its share repurchase capacity. The board grew from ten to twelve members with the appointment of Catherine R. Smith, CFO of Starbucks, and Christophe P. Weber, president and CEO of Takeda Pharmaceutical, effective February 18, 2026.
Smith joins the Audit and Nominating and Governance Committees, while Weber joins the Executive Compensation and Human Resources Committee and the Risk, Science and Technology Committee as of February 23, 2026. Each will receive prorated non-employee director compensation, including a cash retainer of approximately $24,663 and an equity award valued at approximately $42,420, vesting at the end of their terms.
The board also approved an increase to the company’s existing common stock repurchase authorization by an additional $4.0 billion, bringing the total authorization to $5.0 billion, all of which remains available under the stock repurchase program.
Boston Scientific EVP Padraig Andrew O'Connor reported multiple equity award transactions. On February 13, 14, and 16, 2026, restricted stock units covering 500, 1,190, and 905 units were exercised or converted into an equal number of Boston Scientific common shares at a stated price of $0.00 per share.
Related Form 4 entries show dispositions of 199, 449, and 339 common shares at $74.73 per share, characterized as payments of tax liability by delivering shares rather than open-market sales. Footnotes explain that each restricted stock unit represents a commitment to issue one share, generally in four equal annual installments beginning on specified February anniversaries of the grant dates.
Boston Scientific SVP Emily Woodworth reported several equity transactions involving restricted stock units and common stock. On February 13–16, 2026, she exercised restricted stock units that convert into an equal number of Boston Scientific common shares, with individual transactions including 1,413, 661, and 637 units. Corresponding common stock entries show the same share amounts acquired at a stated price of $0.0000 per share, reflecting non-cash derivative exercises. Additional common stock entries coded “F” cover 690, 296, and 283 shares delivered at $74.73 per share to satisfy tax liabilities rather than open-market sales. Footnotes state that each restricted stock unit represents a commitment to issue one share of common stock, generally in four equal annual installments beginning on specific grant anniversaries.
Boston Scientific EVP and CFO Jonathan Monson reported a series of equity award transactions. On February 13, 14 and 16, 2026, restricted stock units were converted into common stock in blocks of 1,766, 1,058 and 990 shares at $0.0000 per share, reflecting vesting of prior grants. On each date, portions of the resulting common shares (788, 470 and 440 shares) were disposed of at $74.73 per share to satisfy tax obligations through share withholding. Following these transactions, Monson directly owned 37,986 shares of Boston Scientific common stock.
Boston Scientific senior vice president and chief HR officer Miriam O'Sullivan reported multiple equity award transactions in mid‑February. She exercised restricted stock units into 588, 1,124, and 990 shares of common stock on February 13, 14, and 16, 2026 at a price of $0.00 per share.
To cover tax obligations, she disposed of 200, 329, and 291 common shares on the same dates through tax‑withholding transactions at $74.73 per share. After these moves, she directly held 17,302 Boston Scientific shares and indirectly held 1,731 shares through her spouse.